<DOC>
	<DOCNO>NCT02528110</DOCNO>
	<brief_summary>The efficacy HIPEC prevention local recurrence , distant metastasis peritoneal metastasis locally advance gastric cancer definite . The hypothesis trial radical gastrectomy plus HIPEC superior radical gastrectomy term overall survival .</brief_summary>
	<brief_title>Radical Gastrectomy Hyperthermic Intraperitoneal Chemotherapy ( HIPEC ) Locally Advanced Gastric Cancer</brief_title>
	<detailed_description>To determine efficacy HIPEC treatment locally advance gastric cancer , patient randomize HIPEC group control group . In HIPEC group , patient undergo radical gastrectomy D2 lymphadenectomy HIPEC paclitaxel 5-Fu . Patients control group undergo radical gastrectomy D2 lymphadenectomy . Patients group receive 6 cycle postoperative chemotherapy ( SOX XELOX ) follow 5 year death . The trial design prospective , randomize , open , multicenter parallel group study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<criteria>Histological prove diagnosis locally advance gastric cancer . No evidence distant metastasis peritoneal metastasis . Preoperative examination ( CT/MRI ) demonstrate resectable gastric cancer T3T4 stage . Eligible radical gastrectomy D2 lymphadenectomy . Have receive cytotoxic chemotherapy radiotherapy . Written inform consent obtain prior commencement trial treatment . Existence distant metastasis peritoneal metastasis surgery ( M1 ) . Any previous chemotherapy radiotherapy Active systemic infection Inadequate cardiac function , renal function , liver function bone marrow function begin trial . Female patient pregnant breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>